Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib and Dostarlimab in Advanced Cancers With Brain Metastases (STARLET)
NCT05700721Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2023
- Primary completion
- Dec 2029
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib and dostarlimab in brain metastases, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Intracranial Objective Response Rate and Incidence of Adverse Events at 1 year. Started Jun 2023; status: recruiting.
02
Drugs
niraparibdostarlimab
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT05700721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05700721.